Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental ...

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top cheap pharmaceutical stocks to buy now. Morgan Stanley analyst ...

Over the past five years, BMY's one-day stock returns following earnings announcements have been evenly split: ...

BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: refractory disease to first-line chemoimmunotherapy or relapse within 12 months of ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...